search
Back to results

Canadian Health Advanced By Nutrition and Graded Exercise (CHANGE)

Primary Purpose

Metabolic Syndrome

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Dietary Intervention
Exercise Prescription and Fitness Program
Sponsored by
Daren K. Heyland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome focused on measuring central obesity, abdominal obesity, hypertension, cardiovascular disease, high cholesterol, high triglycerides, insulin resistance, diabetes mellitus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age >/= 18 years old
  • Fasting Blood Glucose >/= 5.6 mmol/L or receiving pharmacotherapy
  • Blood Pressure of >/= 130/85 mm Hg or receiving pharmacotherapy
  • Triglyceride of >/= 1.7 mmol/L or receiving pharmacotherapy
  • HDL-C < 1.0 mmol/L Males and < 1.3 mmol/L females
  • Abdominal circumference as determined by a pre-specified technique:
  • Europids/Whites/sub-Saharan Africans/Mediterranean/middle east >/= 94 cm Males, >/= 80 cm Female.
  • Asian and South Central Americans >/= 90 cm males and >/=80 cm females
  • US and Canadian Whites >/= 102 cm males, >/=88 cm females.

Exclusion Criteria:

  • Inability to speak, read or understand English and/or French for the Laval University participants.
  • Having a medical or physical condition that makes moderate intensity physical activity difficult or unsafe.
  • Diagnosis of Type 1 Diabetes Mellitus
  • Type 2 diabetes mellitus only if any one of the following are present

    1. Proliferative diabetic retinopathy
    2. Nephropathy (Suggested parameters: serum creatinine > 160 µmol/L)
    3. Clinically manifest neuropathy defined as absent ankle jerks
    4. Severe fasting hyperglycemia > 11 mmol/L
    5. Peripheral vascular disease
  • Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, renal , liver), heart disease, stroke and ongoing substance abuse
  • Clinically significant renal failure
  • Diagnosis of psychiatric disorders (cognitive impairment) that would limit adequate informed consent or ability to comply with study protocol
  • Diagnosis of cancer (other than non-melanoma skin cancer) that was active or treated with radiation or chemotherapy within the past 2 years
  • Diagnosis of a terminal illness and/or in hospice care
  • Pregnant, lactating or planning to become pregnant during the study period
  • Investigator discretion for clinical safety or protocol adherence reasons
  • Chronic inflammatory diseases
  • Body Mass Index > 35

Sites / Locations

  • Edmonton Oliver Primary Care Network
  • Canadian Phase Onward Inc.
  • Clinique de kinésiologie de l'Université Laval

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Diet and exercise

Arm Description

A combined diet and exercise program tailored to individuals incorporating behavioural modification support

Outcomes

Primary Outcome Measures

Feasibility of the Diet Intervention
Percentage of the prescribed diet visits visits attended over 12 months. Each participant was to attend a total of 21 prescribed diet visits over 12 months.
Feasibility of the Exercise Intervention
Percentage of the prescribed exercise visits attended over 12 months. Each participant was to attend a total of 21 prescribed exercise visits over 12 months.
Number of Participants That Have Reversal of Metabolic Syndrome
Metabolic syndrome is defined as having 3/5 of the following: elevated blood pressure (or on medication), elevated blood sugars (or on medication), elevated triglycerides (or on medication), low HDL-C and a large waist circumference. Reversal of metabolic syndrome is defined as having less than 3/5 criteria

Secondary Outcome Measures

Percentage of Participants With Improvements in at Least One Individual Components of Metabolic Syndrome
Improvements in blood pressure (or elimination of medication), blood sugars (or elimination of medication), triglycerides (or elimination of medication), HDL-C and waist circumference
Change From Baseline in Diet Quality-Canadian Healthy Eating Index
Canadian Health Eating Index (HEI-C) is reported on a 100 point score with a higher score indicating a better outcome. A higher score means a better outcome. HEI-C is on a 100 point score.
Change From Baseline in Diet Quality-Mediterranean Diet Score
Mediterranean Diet Score (MDS) is reported on a 0-14 point score with a higher score indicating a better outcome.
Change From Baseline in Aerobic Capacity
Estimated maximal oxygen consumption (VO2 max) standardized to age and sex
Changes in Risk of Myocardial Infarction and Cardiac Events
Changes in PROCAM score, which estimates the risk of a myocardial infarction or dying from an acute coronary event within the next 10 years. Similar to Framingham risk score but for metabolic syndrome. A lower score means a better outcome. PROCAM score varies from 0-87,0 means there are no risk factors (pt is younger than 39), while 87 means the patient is a smoker and older than 60 years and presents all risk factors
Changes in Continuous Metabolic Syndrome Risk Score
Metabolic syndrome risk score is a composite continuous score that measures the severity of metabolic syndrome as a continuous variable rather than dichotomized with arbitrary cut-points . The score is the principal component of waist circumference, glucose, systolic blood pressure, triglycerides. It has a mean of 0 and a standard deviation of 1 with higher score meaning greater risk. Reference Hillier TA, et al., Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia (2006) 49:1528-1535

Full Information

First Posted
June 7, 2012
Last Updated
January 28, 2021
Sponsor
Daren K. Heyland
Collaborators
St. Joseph's Healthcare Hamilton
search

1. Study Identification

Unique Protocol Identification Number
NCT01616563
Brief Title
Canadian Health Advanced By Nutrition and Graded Exercise
Acronym
CHANGE
Official Title
Canadian Health Advanced By Nutrition and Graded Exercise: CHANGE Health Paradigm
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
October 2012 (Actual)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Daren K. Heyland
Collaborators
St. Joseph's Healthcare Hamilton

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The overall objective of the CHANGE initiative is to change the delivery of care in primary care clinics to treat disease by reducing reliance on drugs and hospitals through the promotion of scientifically validated nutritional concepts and exercise. Specifically, the objective is to identify patients from primary care clinics with metabolic syndrome who are not morbidly obese and use diet and exercise interventions to reverse the changes, reduce reliance on pharmacotherapy and prevent progression to diabetes and cardiovascular disease.
Detailed Description
Hypertension, cardiovascular disease, strokes, diabetes and their complications including renal failure and neuropathy are major contributors to healthcare costs1. Metabolic Syndrome, a widespread genetic trait refers to a group of factors that increase risk for these diseases. Progression of the components of the metabolic syndrome can be significantly reduced by dietary manipulation and exercise. The aging population, with both metabolic syndrome and muscular weakness, is going to result in an enormous social and financial burden not only for medical care but also for families caring for such patients. Existing knowledge would suggest that dietary modification and exercise training would substantially reduce the costs and complications of these medical conditions. The Canadian Guidelines for the diagnosis and management of cardiometabolic risk identify patients with metabolic syndrome who have an increased risk of cardiac and vascular disease and diabetes but the application of these results to prevent disease has been a dismal failure in general and in particular, in our country. The current model of advice about preventive care is through family doctors (FD) in the primary care setting. FDs tend not to advise their patients about diet and exercise for a variety of reasons including a lack of education about these modalities, a lack of support from professionals qualified to assess and advise about diet and exercise, the belief that drugs are better, lack of time and a lack of reimbursement in addition to patient barriers to adoption. Although other factors, such has smoking, hypercoagulability and increased expression of proinflammatory cytokines increase cardiometabolic risk, these changes are closely related to the metabolic syndrome. "Health behavior interventions" are identified as critical to preventing the occurrence of cardiovascular disease and diabetes. These interventions can be associated with appropriate pharmacotherapy where required. The guidelines recommend a multidisciplinary team to manage these interventions. In addition it is also recommended that ethnicity be considered in these interventions. The various traits associated with the metabolic syndrome are strongly influenced by genetic factors, i.e. the heritability of abdominal obesity and insulin resistance are estimated to be as high as 70%. Accordingly, the investigators propose to examine numerous genetic polymorphisms (also referred to as markers) that have been linked to the various traits associated with metabolic syndrome in a sub study. It is hypothesized that these markers can be used as a means to better predict the variable responses observed in individuals following a lifestyle intervention. Several companies have begun to commercialize direct-to-consumer genetic-testing to provide nutritional counseling to individuals based on the analysis of a small subset of polymorphisms11; however, there is an absence of scientific research to either support or refute the value of genetic markers for predicting an individual's response. Considering common genetic markers in a lifestyle intervention study will enable us to assess their value for predicting response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome
Keywords
central obesity, abdominal obesity, hypertension, cardiovascular disease, high cholesterol, high triglycerides, insulin resistance, diabetes mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
305 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Diet and exercise
Arm Type
Experimental
Arm Description
A combined diet and exercise program tailored to individuals incorporating behavioural modification support
Intervention Type
Behavioral
Intervention Name(s)
Dietary Intervention
Other Intervention Name(s)
Nutrition therapy, Dietary counselling, Behavioural therapy
Intervention Description
Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
Intervention Type
Behavioral
Intervention Name(s)
Exercise Prescription and Fitness Program
Other Intervention Name(s)
Exercise plan, physical activity intervention
Intervention Description
Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
Primary Outcome Measure Information:
Title
Feasibility of the Diet Intervention
Description
Percentage of the prescribed diet visits visits attended over 12 months. Each participant was to attend a total of 21 prescribed diet visits over 12 months.
Time Frame
At 12 months
Title
Feasibility of the Exercise Intervention
Description
Percentage of the prescribed exercise visits attended over 12 months. Each participant was to attend a total of 21 prescribed exercise visits over 12 months.
Time Frame
At 12 months
Title
Number of Participants That Have Reversal of Metabolic Syndrome
Description
Metabolic syndrome is defined as having 3/5 of the following: elevated blood pressure (or on medication), elevated blood sugars (or on medication), elevated triglycerides (or on medication), low HDL-C and a large waist circumference. Reversal of metabolic syndrome is defined as having less than 3/5 criteria
Time Frame
At 12 months compared to baseline measures
Secondary Outcome Measure Information:
Title
Percentage of Participants With Improvements in at Least One Individual Components of Metabolic Syndrome
Description
Improvements in blood pressure (or elimination of medication), blood sugars (or elimination of medication), triglycerides (or elimination of medication), HDL-C and waist circumference
Time Frame
At 12 months compared to baseline
Title
Change From Baseline in Diet Quality-Canadian Healthy Eating Index
Description
Canadian Health Eating Index (HEI-C) is reported on a 100 point score with a higher score indicating a better outcome. A higher score means a better outcome. HEI-C is on a 100 point score.
Time Frame
Change at 12 months compared to baseline
Title
Change From Baseline in Diet Quality-Mediterranean Diet Score
Description
Mediterranean Diet Score (MDS) is reported on a 0-14 point score with a higher score indicating a better outcome.
Time Frame
Change at 12 months compared to baseline
Title
Change From Baseline in Aerobic Capacity
Description
Estimated maximal oxygen consumption (VO2 max) standardized to age and sex
Time Frame
Change at 12 months compared to baseline
Title
Changes in Risk of Myocardial Infarction and Cardiac Events
Description
Changes in PROCAM score, which estimates the risk of a myocardial infarction or dying from an acute coronary event within the next 10 years. Similar to Framingham risk score but for metabolic syndrome. A lower score means a better outcome. PROCAM score varies from 0-87,0 means there are no risk factors (pt is younger than 39), while 87 means the patient is a smoker and older than 60 years and presents all risk factors
Time Frame
Change at 12 months compared to baseline
Title
Changes in Continuous Metabolic Syndrome Risk Score
Description
Metabolic syndrome risk score is a composite continuous score that measures the severity of metabolic syndrome as a continuous variable rather than dichotomized with arbitrary cut-points . The score is the principal component of waist circumference, glucose, systolic blood pressure, triglycerides. It has a mean of 0 and a standard deviation of 1 with higher score meaning greater risk. Reference Hillier TA, et al., Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia (2006) 49:1528-1535
Time Frame
Change at 12 months compared to baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >/= 18 years old Fasting Blood Glucose >/= 5.6 mmol/L or receiving pharmacotherapy Blood Pressure of >/= 130/85 mm Hg or receiving pharmacotherapy Triglyceride of >/= 1.7 mmol/L or receiving pharmacotherapy HDL-C < 1.0 mmol/L Males and < 1.3 mmol/L females Abdominal circumference as determined by a pre-specified technique: Europids/Whites/sub-Saharan Africans/Mediterranean/middle east >/= 94 cm Males, >/= 80 cm Female. Asian and South Central Americans >/= 90 cm males and >/=80 cm females US and Canadian Whites >/= 102 cm males, >/=88 cm females. Exclusion Criteria: Inability to speak, read or understand English and/or French for the Laval University participants. Having a medical or physical condition that makes moderate intensity physical activity difficult or unsafe. Diagnosis of Type 1 Diabetes Mellitus Type 2 diabetes mellitus only if any one of the following are present Proliferative diabetic retinopathy Nephropathy (Suggested parameters: serum creatinine > 160 µmol/L) Clinically manifest neuropathy defined as absent ankle jerks Severe fasting hyperglycemia > 11 mmol/L Peripheral vascular disease Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, renal , liver), heart disease, stroke and ongoing substance abuse Clinically significant renal failure Diagnosis of psychiatric disorders (cognitive impairment) that would limit adequate informed consent or ability to comply with study protocol Diagnosis of cancer (other than non-melanoma skin cancer) that was active or treated with radiation or chemotherapy within the past 2 years Diagnosis of a terminal illness and/or in hospice care Pregnant, lactating or planning to become pregnant during the study period Investigator discretion for clinical safety or protocol adherence reasons Chronic inflammatory diseases Body Mass Index > 35
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Khush Jeejeebhoy, MD
Organizational Affiliation
University of Toronto
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Paula Brauer
Organizational Affiliation
University of Guelph
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Angelo Tremblay
Organizational Affiliation
Laval University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
David Mutch, PhD
Organizational Affiliation
University of Guelph
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Doug Klein, MD
Organizational Affiliation
University of Alberta, Edmonton, Alberta
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lew Pliamm, MD
Organizational Affiliation
Canadian Phase Onward
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Caroline Rheaume
Organizational Affiliation
Laval University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Edmonton Oliver Primary Care Network
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
Canadian Phase Onward Inc.
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M3H 5S4
Country
Canada
Facility Name
Clinique de kinésiologie de l'Université Laval
City
Quebec
ZIP/Postal Code
G1K 7P4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
17211012
Citation
Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007 Jan-Feb;26(1):38-48. doi: 10.1377/hlthaff.26.1.38.
Results Reference
background
PubMed Identifier
11832527
Citation
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.
Results Reference
background
PubMed Identifier
21059972
Citation
Balducci S, Zanuso S, Nicolucci A, De Feo P, Cavallo S, Cardelli P, Fallucca S, Alessi E, Fallucca F, Pugliese G; Italian Diabetes Exercise Study (IDES) Investigators. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med. 2010 Nov 8;170(20):1794-803. doi: 10.1001/archinternmed.2010.380.
Results Reference
background
PubMed Identifier
21947643
Citation
Gouveri ET, Tzavara C, Drakopanagiotakis F, Tsaoussoglou M, Marakomichelakis GE, Tountas Y, Diamantopoulos EJ. Mediterranean diet and metabolic syndrome in an urban population: the Athens Study. Nutr Clin Pract. 2011 Oct;26(5):598-606. doi: 10.1177/0884533611416821.
Results Reference
background
PubMed Identifier
21392646
Citation
Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011 Mar 15;57(11):1299-313. doi: 10.1016/j.jacc.2010.09.073.
Results Reference
background
PubMed Identifier
10459869
Citation
Engstrom G, Hedblad B, Janzon L. Hypertensive men who exercise regularly have lower rate of cardiovascular mortality. J Hypertens. 1999 Jun;17(6):737-42. doi: 10.1097/00004872-199917060-00003.
Results Reference
background
PubMed Identifier
21734589
Citation
Rubenfire M, Mollo L, Krishnan S, Finkel S, Weintraub M, Gracik T, Kohn D, Oral EA. The metabolic fitness program: lifestyle modification for the metabolic syndrome using the resources of cardiac rehabilitation. J Cardiopulm Rehabil Prev. 2011 Sep-Oct;31(5):282-9. doi: 10.1097/HCR.0b013e318220a7eb. Erratum In: J Cardiopulm Rehabil Prev. 2011 Nov;31(6):E1.
Results Reference
background
PubMed Identifier
21459257
Citation
Cardiometabolic Risk Working Group: Executive Committee; Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Despres JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol. 2011 Mar-Apr;27(2):e1-e33. doi: 10.1016/j.cjca.2010.12.054.
Results Reference
background
PubMed Identifier
19173724
Citation
Fung CS, Mercer SW. A qualitative study of patients' views on quality of primary care consultations in Hong Kong and comparison with the UK CARE Measure. BMC Fam Pract. 2009 Jan 27;10:10. doi: 10.1186/1471-2296-10-10.
Results Reference
background
PubMed Identifier
18852695
Citation
Lusis AJ, Attie AD, Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet. 2008 Nov;9(11):819-30. doi: 10.1038/nrg2468.
Results Reference
background
PubMed Identifier
21159896
Citation
Imai K, Kricka LJ, Fortina P. Concordance study of 3 direct-to-consumer genetic-testing services. Clin Chem. 2011 Mar;57(3):518-21. doi: 10.1373/clinchem.2010.158220. Epub 2010 Dec 15.
Results Reference
background

Learn more about this trial

Canadian Health Advanced By Nutrition and Graded Exercise

We'll reach out to this number within 24 hrs